piperonyl butoxide
Trade name: Rid Mousse
Approved
Mar 7, 2000
Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is a waxy white solid. It is a semisynthetic derivative of safrole. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist. It has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone. PBO acts as an insecticide synergist by inhibiting the natural defense mechanisms of the insect, the most important of which is the Mixed Function Oxidase system, also known as the cytochrome P-450 system. The MFO system is the primary route of detoxification in insects, and causes the oxidative breakdown of insecticides like pyrethrins and the synthetic pyrethroids - thus when PBO is added, higher insecticide levels remain in the insect to exercise their lethal effect. An important consequence of this property is that, by enhancing the activity of a given insecticide, less may be used to achieve the same result. PBO does not appear to have a significant effect on the MFO system in humans. Skin Sensitization PBO has a low acute toxicity by oral, inhalation and dermal routes. It is minimally irritating to the eyes and skin. It is a not a dermal sensitizer. No evidence suggests that PBO disrupts the normal functioning of the endocrine system. This includes the recently developed data to assess the possible interaction of PBO with the endocrine system. — NCATS
Clinical trial activity
3 trials · 9 clinical orgs · 1 marketing orgs
Earliest trial started Sep 1, 2004 (NCT00381082)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Cytochrome P450INHIBITOR
Cytochrome P450 inhibitor
- Uncharacterized protein (8238086) ↗
- Cytochrome P450, putative (8232915) ↗
- Cytochrome P450 CYP4G38 (8231029) ↗
- Cytochrome P450, putative (8238343) ↗
- Cytochrome P-450, putative (8234840) ↗
- Cytochrome P450, putative (8232678) ↗
- Cytochrome P450, putative (8237618) ↗
- Cytochrome P450, putative (8238380) ↗
- Cytochrome P450, putative (8234407) ↗
- Cytochrome P-450, putative (8237795) ↗
- Cytochrome P-450, putative (8236088) ↗
- Cytochrome P-450, putative (8236974) ↗
- Cytochrome P450, putative (8237447) ↗
- Cytochrome P450, putative (8234408) ↗
- Cytochrome P-450, putative (8238085) ↗
- Cytochrome P-450, putative (8229807) ↗
- Cytochrome P450, putative (8240195) ↗
- Cytochrome P-450, putative (8230924) ↗
- Cytochrome P450, putative (8230507) ↗
- Cytochrome P-450, putative (8233823) ↗
- Cytochrome P-450, putative (8233620) ↗
- Cytochrome P-450, putative (8232310) ↗
- Cytochrome P450, putative (8230937) ↗
- Cytochrome P-450, putative (8236087) ↗
- Cytochrome P-450, putative (8234154) ↗
- Cytochrome P-450, putative (8230957) ↗
- Cytochrome P-450, putative (8233619) ↗
- Cytochrome P-450, putative (8235475) ↗
- Cytochrome P450 CYP302A1 (8230819) ↗
- Cytochrome P450, putative (8231511) ↗
- Cytochrome P450, putative (8236100) ↗
- Cytochrome P-450, putative (8233621) ↗
- Cytochrome P-450, putative (8230508) ↗
- Cytochrome P-450, putative (8238404) ↗
- NADH-Ubiquinone oxidoreductase 39kDa subunit (8239920) ↗
Combination products
rid mousse
with pyrethrins
Approval history
- approvedMar 7, 2000
Chemistry & pharmacology
SMILES
CCCCOCCOCCOCC1=C(CCC)C=C2OCOC2=C1- Mol. weight
- 338.4385 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaPiperonyl butoxide ↗
- NCATSLWK91TU9AH ↗
- ChEMBLCHEMBL1201131 ↗
Also known as
- butacide
- buticide
- butocide
- butoxide
- butyl carbitol 6-propylpiperonyl ether
- piperonyl
- piperonyl butoxide
- piperonyl butoxide
- piperonyl butoxide
- piperonyl butoxide
- piperonyl butoxide
- piperonyl butoxide
- piperonyl butoxide
- piperonyl butoxide
- piperonyl butoxide
- piperonyl butoxide
- rid mousse
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04566510 | N/A | Oct 17, 2020 | National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco, University of London |
| NCT03554616 | N/A | Dec 1, 2018 | Kilimanjaro Christian Medical College, Tanzania, National Institute for Medical Research, Tanzania, University of London, University of Ottawa |
| NCT00381082 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2004 | Ego Pharmaceuticals, Uniquest Pty Ltd, University of Queensland |
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of London | Academic/Hospital | 2 | 1 | 1 | 2018 |
| Ego Pharmaceuticals | For profit | 1 | 0 | 1 | 2004 |
| Kilimanjaro Christian Medical College, Tanzania | Academic/Hospital | 1 | 0 | 1 | 2018 |
| National Institute for Medical Research, Tanzania | Government | 1 | 0 | 1 | 2018 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2020 |
| Uniquest Pty Ltd | Academic/Hospital | 1 | 1 | 1 | 2004 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Ottawa | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Queensland | Academic/Hospital | 1 | 0 | 1 | 2004 |